DNA methyltransferase (DNMT) inhibitors, such as 5-aza-2′-deoxycytidine (5-aza-2′-CdR) or 5-azacytidine, have been approved for cancer treatment by reversing epigenetic silencing of genes to enhance the immunogenic potential of cancer cells [177,178]. This evidence concerns the gene DNMT1 and cancer.